Table 1.
Patient’s characteristic and PGL treatment
| |
DLBCL |
MALT lymphoma |
Others |
|||||
|---|---|---|---|---|---|---|---|---|
|
N |
139 |
83 |
51 |
5 (ATL 2, FL 2, PTCL 1) |
||||
| Age | Median 62 ( range: 19–85) | Median 63 ( range: 20–85) | Median 56 ( range: 19–76) | Median 64 ( range: 53–72) | ||||
| Sex (M : F) |
71 : 68 |
44 : 39 |
25 : 26 |
2 : 3 |
||||
| Stage |
I |
94 |
I |
42 |
I |
48 |
I |
4 |
| (Lugano) |
II |
40 |
II |
37 |
II |
2 |
II |
1 |
| |
IV |
5 |
IV |
4 |
IV |
1 |
|
|
| Treatment |
RT |
50 |
RT |
0 |
RT |
49 |
RT |
1 |
| |
CT+RT |
89 |
CT+RT |
83 |
CT+RT |
2 |
CT+RT |
4 |
| Rituximab |
R+ |
40 |
R+ |
38 |
R+ |
1 |
R+ |
1 |
| |
R- |
99 |
R- |
45 |
R- |
50 |
R- |
4 |
| RT dose |
|
|
40 Gy/20fr |
35 |
30 Gy/15fr |
23 |
40 Gy/20fr |
2 |
| |
40 Gy≧ |
89 |
40.5 Gy/27fr |
45 |
30 Gy/20fr |
24 |
40.5 Gy/27fr |
2 |
| |
40 Gy< |
50 |
44 Gy/22fr |
2 |
36 Gy/18fr |
1 |
36 Gy/18fr |
1 |
| |
|
|
30 Gy/15fr |
1 |
40 Gy/20fr |
1 |
|
|
| |
|
|
|
|
46 Gy/23fr |
2 |
|
|
| Observation length |
mean 61.5 months |
mean 62.7 months |
mean 61.0 months |
mean 46.9 months |
||||
| (range) |
(3.7–124.6) |
(7.1–124.6) |
(3.7–120.4) |
(11.5–82.4) |
||||
| 5 year OS | 92.0% | 89.6% | 97.7% | 75.0% | ||||
PGL: primary gastric lymphoma.
DLBCL: diffuse large B-cell lymphoma.
MALT: mucosa-associated lymphoid tissue.
ATL: adult T-cell lymphoma.
FL: follicular lymphoma.
PTCL: peripheral T-cell lymphoma.
RT: radiotherapy.
CT: chemotherapy.
OS: overall survival.
R: rituximab.